Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

Seema A Bhat, MD, Ying Huang, MS, MA, Amy S. Ruppert, PhD, James S. Blachly, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Kerry A. Rogers, MD, Gerard Lozanski, MD, Nyla A Heerema, PhD, Lynne V. Abruzzo, MD PhD, Cecelia Miller, PhD, Jennifer Zvosec, CCRP, Kasturi Ganesh-Barki, MBBS, John C. Byrd, MD, Jennifer A. Woyach, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-138612

Published: 2020

Journal Articles

Clinical and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia (Alliance)

Sydney Fobare, Jessica Kohlschmidt, PhD, Hatice Gulcin Ozer, PhD, Krzysztof Mrózek, MDPhD, Deedra Nicolet, MS, Alice S. Mims, MD, Ramiro Garzon, MD, James S. Blachly, MD, Shelley Orwick, BS, Andrew J Carroll, PhD, Richard M. Stone, MD, Eunice S. Wang, MD, Jonathan E. Kolitz, MD, Bayard L. Powell, MD, Christopher C. Oakes, PhD, Ann-Kathrin Eisfeld, MD, Erin Hertlein, PhD, John C. Byrd, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-135887

Published: 2020

Journal Articles

Evaluation of the Incidence and Risk Factors Associated with Major Cardiovascular Events in Patients Receiving Acalabrutinib Therapy

Leylah Azali, PharmD, Lindsay Hazelden, PharmD, Tracy Wiczer, PharmD, Marilly Palettas, Rebekah Thomas, Connor Aossey, James S. Blachly, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Kerry A. Rogers, MD, John C. Byrd, MD, Jennifer A. Woyach, MD, Daniel Addison, MD, Seema A Bhat, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-137800

Published: 2020

Journal Articles

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Third-Party Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Sumithira Vasu, MDMBBS, Bhavana Bhatnagar, DO, James S. Blachly, MD, Nicole Szuminski, BS, Lynn O'Donnell, PhD, Dean Anthony Lee, MD PhD

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-139170

Published: 2020

Journal Articles

Differential Impact of Prognostically Significant Gene Mutations in Acute Myeloid Leukemia (AML) Patients (Pts) Older Than 70 Years (y) Treated with Cytarabine-Based Induction Therapy

Marius Bill, MD PhD, Jessica Kohlschmidt, PhD, Krzysztof Mrózek, MDPhD, Deedra Nicolet, MS, Christopher J. Walker, PhD, Dimitrios Papaioannou, MD, James S. Blachly, MD, Shelley Orwick, BS, Eunice S. Wang, MD, Jonathan E. Kolitz, MD, Bayard L. Powell, MD, Andrew J Carroll, PhD, Ramiro Garzon, MD, Richard M. Stone, MD, John C. Byrd, MD, Clara D. Bloomfield, MD, Ann-Kathrin Eisfeld, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-141663

Published: 2020

Journal Articles

Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance)

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-140999

Published: 2020

Journal Articles

Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia

Jennifer A. Woyach, MD, James S. Blachly, MD, Kerry A. Rogers, MD, Seema A Bhat, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Mojgan Jianfar, MD, Gerard Lozanski, MD, David M. Weiss, Barbara L. Andersen, PhD, Priti Patel, MD, Veerendra Munugalavadla, PhD, Anna Butturini, MD, Yan Xu, Min Hui Wang, PhD, John C. Byrd, MD

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-136317

Published: 2020

Journal Articles

Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations

Jennifer Woyach, MD, Ying Huang, MS, MA, Kerry Rogers, Seema A. Bhat, MD, Michael R. Grever, MD, Arletta Lozanski, Tzyy-Jye Doong, James S. Blachly, MD, Gerard Lozanski, MD, Dan Jones, MD PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 504.

https://doi.org/10.1182/blood-2019-127674

Published: 2019

Journal Articles

Identification of Novel Synthetic Lethal Partners of NAMPT Inhibitor By CRISPR-Cas9 Screens in Acute Myeloid Leukemia

Pu Zhang, Lindsey Brinton, PhD, James S. Blachly, MD, John C. Byrd, MD, Rosa Lapalombella, PhD

Blood (2019) 134 (Supplement_1): 2072.

https://doi.org/10.1182/blood-2019-129036

Published: 2019

Journal Articles

The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia

Elizabeth M. Muhowski, Amy M. Lehman, M.A.S, Sean D. Reiff, PhD, Janani Ravikrishnan, Rose Mantel, Shrilekha Misra, Michael Niesman, PhD, Kai Zhang, MD, James S. Blachly, MD, Deepa Sampath, PhD, John C. Byrd, MD, Jennifer Woyach, MD

Blood (2019) 134 (Supplement_1): 2077.

https://doi.org/10.1182/blood-2019-128871

Published: 2019

Journal Articles

NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy

Bhavana Bhatnagar, DO, Shelley Orwick, BS, Nyla A. Heerema, PhD, Alison R. Walker, MD, Alice S. Mims, MD, James S. Blachly, MD, Karilyn Larkin, MD, Nicole Grieselhuber, MD PhD, Gregory K. Behbehani, MD PhD, Apollinaire Ngankeu, Charles Thomas Gregory, BS, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1329.

https://doi.org/10.1182/blood-2019-130856

Published: 2019

Journal Articles

DNA Methylation-Based Classification Highlights the Role of the JAK-STAT Pathway in Acute Myeloid Leukemia

Brian Giacopelli, BS, Min Wang, Ada C Cleary, Yue-zhong Wu, MSc, Anna Reister Schultz, James S. Blachly, MD, Ann-Kathrin Eisfeld, MD, Kevin R Coombes, Clara D. Bloomfield, MD, Brian J. Druker, Jeffrey W. Tyner, John C. Byrd, MD, Christopher C. Oakes, PhD

Blood (2019) 134 (Supplement_1): 1413.

https://doi.org/10.1182/blood-2019-126212

Published: 2019

Journal Articles

Rapid Molecular Diagnostics for Acute Myeloid Leukemia Using Single-Molecule Sequencing

Esko A. Kautto, BS, Charles Thomas Gregory, BS, Caner Saygin, MD, Shelley Orwick, BS, James S. Blachly, MD

Blood (2019) 134 (Supplement_1): 374.

https://doi.org/10.1182/blood-2019-131366

Published: 2019

Journal Articles

Genomic Analysis of Cellular Hierarchy in Acute Myeloid Leukemia Using Ultrasensitive LC-FACS-Seq

Caner Saygin, MD, Arletta Lozanski, Tzyy-Jye Doong, Shelley Orwick, BS, Deedra Nicolet, MS, Jadwiga Labanowska, Nyla A. Heerema, PhD, Rosa Lapalombella, PhD, Gregory K. Behbehani, MD PhD, John C. Byrd, MD, Gerard Lozanski, MD, James S. Blachly, MD

Blood (2019) 134 (Supplement_1): 186.

https://doi.org/10.1182/blood-2019-125285

Published: 2019

Journal Articles

Enumerating Functional HSC Clones in the Zebrafish Using Gestalt

Emily M Teets, B.S., Charles Thomas Gregory, BS, Jami L Shaffer, B.S., James S. Blachly, MD, Bradley W Blaser, MD PhD

Blood (2019) 134 (Supplement_1): 3724.

https://doi.org/10.1182/blood-2019-131503

Published: 2019

Journal Articles

Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia

Janani Ravikrishnan, Tzung-Huei Lai, PhD DVM, Elizabeth Muhowski, Lindsey Brinton, PhD, Katie Williams, MS, Alexandria Thompson, James S. Blachly, MD, Hatice Gulcin Ozer, PhD, John C. Byrd, MD, Rosa Lapalombella, PhD, Jennifer Woyach, MD, Deepa Sampath, PhD

Blood (2019) 134 (Supplement_1): 2526.

https://doi.org/10.1182/blood-2019-128574

Published: 2019

Journal Articles

The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patients Requiring Additional or Alternative Treatment

Ann-Kathrin Eisfeld, MD, Jessica Kohlschmidt, PhD, Krzysztof Mrózek, MD PhD, Deedra Nicolet, MS, Alice S. Mims, MD, Dimitrios Papaioannou, MD, Christopher J. Walker, PhD, James S. Blachly, MD, Sophia E. Maharry, Andrew J. Carroll, PhD, Richard M. Stone, MD, Bayard L Powell, MD, Albert de la Chapelle, MD PhD, Eunice S. Wang, MD, Jonathan E. Kolitz, MD, John C. Byrd, MD, Clara D. Bloomfield, MD

Blood (2019) 134 (Supplement_1): 2681.

https://doi.org/10.1182/blood-2019-130076

Published: 2019

Journal Articles

LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia

Eileen Hu, BS, Hatice Gulcin Ozer, PhD, Arletta Lozanski, Tzyy-Jye Doong, Chi-Ling Chiang, PhD, Seema A. Bhat, MD, Kerry A. Rogers, MD, Jennifer Woyach, MD, James S. Blachly, MD, Gerard Lozanski, MD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 3377.

https://doi.org/10.1182/blood-2019-126070

Published: 2019

Journal Articles

NAMPT Inhibitor KPT-9274 Selectively Targets Self-Renewal Capacity in Acute Myeloid Leukemia

Shaneice Renee Mitchell, BS, Nicole Grieselhuber, MD PhD, Yerdanos Asemelash, Matthew Cannon, BA, Shelley Orwick, BS, Pratibha Sharma, PhD, Virginia Goettl, DVM, PhD, Vinay K Puduvalli, MD MBBS, Deepa Sampath, PhD, Alice S. Mims, MD, James S. Blachly, MD, Amy M. Lehman, PhD, Bonnie K. Harrington, DVM, Justin Breitbach, Erkan Baloglu, William Senapedis, PhD, Rosa Lapalombella, PhD, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 3931.

https://doi.org/10.1182/blood-2018-99-119358

Published: 2018

Journal Articles

Additional Gene Mutations Refine the 2017 European Leukemianet (ELN) Classification of Adult Patients (Pts) with De Novo Acute Myeloid Leukemia (AML) Aged <60 Years: An Analysis of Alliance for Clinical Trials in Oncology (Alliance) Studies

Ann-Kathrin Eisfeld, MD, Jessica Kohlschmidt, PhD, Krzysztof Mrózek, MD PhD, Alice S. Mims, MD, Christopher J. Walker, PhD, Deedra Nicolet, MS, James S. Blachly, MD, Andrew J. Carroll, PhD, Jonathan E. Kolitz, MD, Bayard L. Powell, MD, Richard M. Stone, MD, Albert de la Chapelle, MD PhD, John C. Byrd, MD, Clara D. Bloomfield, MD

Blood (2018) 132 (Supplement 1): 2740.

https://doi.org/10.1182/blood-2018-99-119994

Published: 2018

NARROW

Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

Clinical and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia (Alliance)

Evaluation of the Incidence and Risk Factors Associated with Major Cardiovascular Events in Patients Receiving Acalabrutinib Therapy

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Third-Party Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Differential Impact of Prognostically Significant Gene Mutations in Acute Myeloid Leukemia (AML) Patients (Pts) Older Than 70 Years (y) Treated with Cytarabine-Based Induction Therapy

Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance)

Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia

Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations

Identification of Novel Synthetic Lethal Partners of NAMPT Inhibitor By CRISPR-Cas9 Screens in Acute Myeloid Leukemia

The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia

NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy

DNA Methylation-Based Classification Highlights the Role of the JAK-STAT Pathway in Acute Myeloid Leukemia

Rapid Molecular Diagnostics for Acute Myeloid Leukemia Using Single-Molecule Sequencing

Genomic Analysis of Cellular Hierarchy in Acute Myeloid Leukemia Using Ultrasensitive LC-FACS-Seq

Enumerating Functional HSC Clones in the Zebrafish Using Gestalt

Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia

The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patients Requiring Additional or Alternative Treatment

LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia

NAMPT Inhibitor KPT-9274 Selectively Targets Self-Renewal Capacity in Acute Myeloid Leukemia

Additional Gene Mutations Refine the 2017 European Leukemianet (ELN) Classification of Adult Patients (Pts) with De Novo Acute Myeloid Leukemia (AML) Aged <60 Years: An Analysis of Alliance for Clinical Trials in Oncology (Alliance) Studies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only